Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Total Valuation
Gilead Sciences has a market cap or net worth of $182.03B. The enterprise value is $199.06B.
Market Cap$182.03B
Enterprise Value$199.06B
Share Statistics
Gilead Sciences has 1,241,420,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,241,420,500
Owned by Insiders0.09%
Owned by Institutions5.09%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.38 and return on invested capital (ROIC) is 21.74%.
Return on Equity (ROE)0.38
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)21.74%
Return on Capital Employed (ROCE)0.25
Revenue Per Employee1.67M
Profits Per Employee483.52K
Employee Count17,600
Asset Turnover0.50
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of Gilead Sciences is 17.9. Gilead Sciences’s PEG ratio is 0.01.
PE Ratio17.9
PS Ratio5.19
PB Ratio6.75
Price to Fair Value6.75
Price to FCF16.15
Price to Operating Cash Flow18.13
PEG Ratio0.01
Income Statement
In the last 12 months, Gilead Sciences had revenue of 29.44B and earned 8.51B in profits. Earnings per share was 6.84.
Revenue29.44B
Gross Profit25.52B
Operating Income11.82B
Pretax Income9.80B
Net Income8.51B
EBITDA10.82B
Earnings Per Share (EPS)6.84
Cash Flow
In the last 12 months, operating cash flow was 10.02B and capital expenditures -563.00M, giving a free cash flow of 9.46B billion.
Operating Cash Flow10.02B
Free Cash Flow9.46B
Free Cash Flow per Share7.62
Dividends & Yields
Gilead Sciences pays an annual dividend of $0.79, resulting in a dividend yield of 2.52%
Dividend Per Share$0.79
Dividend Yield2.52%
Payout Ratio38.58%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change31.72%
50-Day Moving Average138.18
200-Day Moving Average120.54
Relative Strength Index (RSI)52.08
Average Volume (3m)7.59M
Important Dates
Gilead Sciences upcoming earnings date is Apr 23, 2026, After Close (Confirmed).
Last Earnings DateFeb 10, 2026
Next Earnings DateApr 23, 2026
Ex-Dividend Date―
Financial Position
Gilead Sciences as a current ratio of 1.68, with Debt / Equity ratio of 108.73%
Current Ratio1.68
Quick Ratio1.31
Debt to Market Cap0.16
Net Debt to EBITDA1.57
Interest Coverage Ratio11.54
Taxes
In the past 12 months, Gilead Sciences has paid 1.29B in taxes.
Income Tax1.29B
Effective Tax Rate0.13
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 15.69, with an EV/FCF ratio of 17.95.
EV to Sales5.76
EV to EBITDA15.69
EV to Free Cash Flow17.95
EV to Operating Cash Flow16.94
Balance Sheet
Gilead Sciences has $10.61B in cash and marketable securities with $24.59B in debt, giving a net cash position of -$13.99B billion.
Cash & Marketable Securities$10.61B
Total Debt$24.59B
Net Cash-$13.99B
Net Cash Per Share-$11.27
Tangible Book Value Per Share-$2.15
Margins
Gross margin is 80.80%, with operating margin of 40.14%, and net profit margin of 28.90%.
Gross Margin80.80%
Operating Margin40.14%
Pretax Margin33.27%
Net Profit Margin28.90%
EBITDA Margin36.75%
EBIT Margin36.75%
Analyst Forecast
The average price target for Gilead Sciences is $158.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$158.00
Price Target Upside7.75% Upside
Analyst ConsensusStrong Buy
Analyst Count21
Revenue Growth Forecast2.76%
EPS Growth Forecast6407.19%